Your browser doesn't support javascript.
loading
Serum sickness-like reaction to D-supplement: a case report.
Plante, Emma R; Ekwunwa, Charles; Maciag, Michelle C; Illanes, Diego.
Afiliação
  • Plante ER; Department of Gynecology and Urogynecology, Milford Regional Medical Center, 14 Prospect Street, Milford, MA, 01757, USA. emmaplante19@gmail.com.
  • Ekwunwa C; Department of Obstetrics and Gynecology, Tufts University School of Medicine, 800 Washington St, Boston, MA, 02111, USA.
  • Maciag MC; Asthma and Allergy Affiliates, 114R Highland Ave, Salem, MA, 01970, USA.
  • Illanes D; Division of Allergy and Immunology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
BMC Pediatr ; 24(1): 404, 2024 Jun 22.
Article em En | MEDLINE | ID: mdl-38909179
ABSTRACT

BACKGROUND:

Serum Sickness-Like Reaction (SSLR) is an immune response characterized by rash, polyarthralgias, inflammation, and fever. Serum sickness-like reaction is commonly attributed to antibiotics, anticonvulsants, and anti-inflammatory agents. CASE PRESENTATION A 16-year-old female with a history of overactive bladder and anemia presented with a diffuse urticarial rash, headaches, joint pain, and swelling for three days. Her medications included oral contraceptive pills, iron, mirabegron, UQora, and a probiotic. Physical examination revealed a diffuse urticarial rash, and her musculoskeletal exam revealed swelling and tenderness in her wrists. She was evaluated by her pediatrician and started on a 7-day course of prednisone, as well as antihistamines. Her CBC, basic metabolic panel, liver function panel, Lyme titers, and urinalysis were all within normal limits. With concern for hypersensitivity reaction to medication, all medications were discontinued. Nine days after symptom onset, the patient was evaluated by an allergist, who confirmed her presentation was consistent with serum sickness-like reaction. Her symptoms resolved, and her medications were re-introduced sequentially over several months. Restarting UQora, however, triggered a recurrence of her symptoms, and it was identified as the culprit medication. Consequently, UQora was permanently discontinued, and the patient has remained symptom-free.

CONCLUSIONS:

This case report describes the first documented case of serum sickness-like reaction caused by UQora (active ingredient D-mannose). D-mannose is a monosaccharide, and it is frequently promoted to prevent urinary tract infections. While the clinical features and timeline in this case were typical of serum sickness-like reaction, UQora as the trigger was highly unusual. Clinicians should be aware of the diverse triggers of serum sickness-like reaction and the importance of prompt identification and management to enhance patient safety. Further research is necessary to better understand the potential therapeutic applications of D-mannose, as well as the potential risks and interactions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença do Soro Limite: Adolescent / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença do Soro Limite: Adolescent / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article